| |
Quarter Ended |
Year Ended |
| |
30.06.2010 |
30.06.2009 |
31.03.2010
(Audited) |
| |
1441.03
|
|
|
| |
13.65
|
|
|
| |
1427.38
|
|
|
| |
52.38
|
|
|
| Total Operating Income (a+b) |
1479.76
|
1373.95
|
5624.91
|
| 2. Expenditure |
| |
a) (Increase)/decrease
in Stock-in-trade and work in progress |
|
20.86
|
(59.20)
|
(184.09)
|
| |
b)
Consumption of
Materials |
|
522.47
|
518.60
|
2033.01
|
| |
c)
Purchase of Traded
Goods |
|
126.90
|
147.25
|
621.66
|
| |
137.56
|
95.02
|
371.08
|
| |
54.82
|
45.81
|
187.84
|
| |
321.37
|
330.76
|
1430.09
|
| |
1183.98
|
1078.24
|
4459.59
|
3. |
Profit (+)/Loss (-) from Operations before
Other Income and Interest & Exceptional Items (1-2) |
|
295.78
|
295.71
|
1165.32
|
| 4. Other Income |
16.75
|
11.97
|
88.33
|
5.
|
Profit (+)/Loss (-) before Interest & Exceptional Items (3+4) |
|
312.53
|
307.68
|
1253.65
|
| 6. Interest |
0.11
|
10.47
|
23.66
|
7.
|
Profit (+)/Loss (-) after Interest but before & Exceptional Items
(5-6) |
|
312.42
|
297.21
|
1229.99
|
|
|
|
|
|
9. |
Profit (+)/Loss (-) before Tax (7+8) |
|
|
|
|
10. Tax Expense
a) Current Tax
b) Deferred Tax
|
|
|
|
11. |
Net Profit (+)/Loss (-) after Tax (9-10) |
|
257.42
|
241.71
|
1081.49
|
12.
|
Paid-up Equity Share Capital (Face Value Rs.2/- per share) |
|
160.58
|
155.46
|
160.58
|
13. |
Reserves excluding Revaluation
Reserves as per Balance Sheet of previous Accounting Year
|
|
|
|
5744.54
|
14. |
Earning per Share (Rs.)
*Not Annualised
|
|
*3.21
|
*3.11
|
13.69
|
15. |
Public Shareholding
- Number of Shares
- Percentage of Shareholding
|
|
|
|
|
16. |
Promoters and Promoter Group Shareholding |
| |
|
|
a)
Pledged/Encumbered
|
|
- |
Number of Shares |
|
- |
Percentage
of shares (as a % of the total shareholding of
promoter and promoter group) |
|
- |
Percentage
of shares (as a % of the total share capital of
the Company) |
| |
|
|
b) Non
Encumbered |
|
-
|
Number
of Shares |
|
-
|
Percentage
of shares (as a % of the total shareholding of
promoter and promoter group) |
|
-
|
Percentage of shares (as a % of the
total share capital of the Company) |
|
NIL
NIL
NIL
295485978
100.00
36.80
|
NIL
NIL
NIL
306108047
100.00
39.38
|
NIL
NIL
NIL
295485978
100.00
36.80
|
| Notes:
- The Company is essentially in the pharmaceutical business segment.
- No investor grievances were pending at the beginning of the quarter. During the quarter ended 30th June, 2010, six investor grievances were received. As of 30th June, 2010 all grievances have been suitably replied to.
- In 2003 the Company received notice of demand from the National Pharmaceutical Pricing Authority, Government of India on account of alleged overcharging in respect of certain drugs under the Drug Price Control Order. This was contested before the jurisdictional High courts wherein it was held in favour of the Company. The orders were challenged before the Hon'ble Supreme Court by the Government. The Hon'ble Supreme Court by separate orders restored the matter to the jurisdictional High Court for interpreting the Drug Policy on the basis of directions and principles laid down by them and also restrained the Government from taking any coercive action against the Company. The Company has been legally advised that on the basis of these orders there is no probability of demand crystallising. Hence no provision is considered necessary in respect of notice of demand aggregating to Rs.1157.12 crores (inclusive of interest) for the period July 1995 to April 2009.
- The figures of the previous year have been regrouped/recast to render them comparable with the figures of the current year.
- The above results after being reviewed by the Audit Committee were approved at the meeting of the Board of Directors held on 13th August, 2010. Limited Review as required under Clause 41 of the Listing Agreement has been completed by the Statutory Auditors of the Company.
|
|
|
Quarter Ended |
| |
|
|
|
| Domestic |
675.15
|
651.89
|
3.6%
|
| |
|
|
|
| |
625.72
|
|
|
| |
|
|
|
| Total Exports |
|
|
|
% of exports to total sales
|
|
|
|
| |
|
|
|
| Total Sales |
|
|
|
| |
|
|
|
| Other operating income |
|
|
|
|
|
|
|
| |
|
|
|
| |
|
|
|
| Income from Operations |
|
|
|
| |
|
|
|
| Material Cost |
|
|
|
| |
|
|
|
| |
|
|
|
| Operating margin |
|
|
|
% to income from operations
|
|
|
|
| |
|
|
|
| Profit before tax |
|
|
|
% to income from operations
|
|
|
|
| |
|
|
|
| Profit after tax |
|
|
|
% to income from operations
|
|
|
|
During the quarter, the company posted a growth of about 8% in income from operations. While domestic sales grew by about 4%, export sales grew by more than 11%. Exports of formulations grew by more than 14% whereas exports of APIs & others have been almost equal. The lower growth in domestic sales is primarily due to sale of ipill business and lower sales of certain products in the domestic generic business. However, the growth in branded generics for the quarter was about 11%.
Material cost has marginally increased and operating margins has decreased (in percentage terms) on a year-on-year basis due to changes in product mix. However, on a quarter-on-quarter basis, operating margins have improved from about 19% to more than 23%.
The increase in staff cost (Rs. 42 cr) is due to annual increments, increase in manpower – in particular at Indore, SEZ and regrouping of contractual staff at Goa facilities. Interest cost has decreased due to repayment of short-term working capital loans availed by the company. Depreciation has increased by about Rs. 9 cr due to additions to fixed assets mainly on account of commissioning of Indore SEZ factory.
The Company has provided for tax under Minimum Alternate Tax (MAT) .
|
